The US Non-Hodgkin Lymphoma therapeutics market size stood at around USD XX billion in 2019 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.
Non-Hodgkin’s lymphomas (NHL) is a distinct group of blood cancer, which includes large variety of lymphomas, excluding Hodgkin’s lymphomas. Non-Hodgkin’s lymphoma (NHL) varies in their severity, from mild to fatal. It is condition where abnormal lymphocytes are produced in the human body. These lymphocytes do not die and keep growing and dividing within the body unless treated. NHL is generally located at lymph nodes, however, if not treated in time then it might spread to the entire lymphatic system
Important factors which are driving the market growth include a rise in the prevalence of NHL, demand for innovative drugs and novel technologies, and an increase in the number of FDA approvals for NHL therapy drugs. In addition, an increase in people awareness about NHL, robust drug pipeline for the treatment of the disease and improved diagnostic techniques to detect NHL. The rapid increases in Non-Hodgkin incidence and mortality rates have been reported in the United States
Major types of Non-Hodgkin Lymphoma
Major types for Non-Hodgkin Lymphoma are B-cell Lymphoma and T-cell Lymphoma. The prevalence of B-cell lymphoma in US is 19.6 cases per 100,000 person-years for both sexes. T-cell lymphomas make up less than 15% of non-Hodgkin lymphomas in the United States